NAD+ Precursor Supplementation to Reverse Poly(ADP-ribose) Polymerase-Driven Me…

Mechanistic description

NAD+ Precursor Supplementation to Reverse Poly(ADP-ribose) Polymerase-Driven Metabolic Catastrophe

Mechanism / pathway

PARP1, SIRT1/3, NAD+
→
metabolomics

Evidence for (4)

Postmortem AD hippocampus shows 60-70% reduction in NAD+ concentration with corresponding PARP1 hyperactivation

PMID:23974067
NMN administration in 5xFAD mice restores cerebral NAD+ levels, improves mitochondrial function, and reduces amyloid plaque burden

PMID:29198525
Human trials of NR in older adults demonstrate safe NAD+ boosting and improvements in mitochondrial biomarkers in blood

PMID:31477785
SIRT3 deacetylase activity declines in AD brain, leading to hyperacetylated SOD2 and increased oxidative stress

PMID:25416150

Evidence against (4)

NAD+ repletion in aged humans shows peripheral effects but unclear brain benefits - no direct CNS NAD+ measurement

PMID:31477785
PARP1 knockout mice show no protection against AD-like pathology - genetic deletion does not prevent amyloid deposition in APP/PS1 mice

PMID:29967475
PARP1 as primary NAD+ consumer is disputed - relative contributions of PARP1, SIRT1, SIRT2, CD38 vary by cell type

PMID:28424515
NMN supplementation studies use supraphysiological doses - mouse studies require doses unlikely achievable in humans

PMID:29198525

Evidence matrix

4 supporting 4 contradicting

53% posterior support

Supporting

Postmortem AD hippocampus shows 60-70% reduction in NAD+ concentration with corresponding PARP1 hyperactivation PMID:23974067
NMN administration in 5xFAD mice restores cerebral NAD+ levels, improves mitochondrial function, and reduces amyloid plaque burden PMID:29198525
Human trials of NR in older adults demonstrate safe NAD+ boosting and improvements in mitochondrial biomarkers in blood PMID:31477785
SIRT3 deacetylase activity declines in AD brain, leading to hyperacetylated SOD2 and increased oxidative stress PMID:25416150

Contradicting

NAD+ repletion in aged humans shows peripheral effects but unclear brain benefits - no direct CNS NAD+ measurement PMID:31477785
PARP1 knockout mice show no protection against AD-like pathology - genetic deletion does not prevent amyloid deposition in APP/PS1 mice PMID:29967475
PARP1 as primary NAD+ consumer is disputed - relative contributions of PARP1, SIRT1, SIRT2, CD38 vary by cell type PMID:28424515
NMN supplementation studies use supraphysiological doses - mouse studies require doses unlikely achievable in humans PMID:29198525

Bayesian persona consensus

53% posterior support

1 signal · 1 for / 0 against · agreement 100%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.

Cite this hypothesis

Citation

etl-backfill (2026). NAD+ Precursor Supplementation to Reverse Poly(ADP-ribose) Polymerase-Driven Me…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-ab3a0af5

BibTeX

@misc{scidex_hypothesis_hab3a0af,
  title        = {NAD+ Precursor Supplementation to Reverse Poly(ADP-ribose) Polymerase-Driven Me…},
  author       = {etl-backfill},
  year         = {2026},
  howpublished = {SciDEX hypothesis},
  url          = {https://prism.scidex.ai/hypotheses/h-ab3a0af5},
  note         = {SciDEX artifact hypothesis:h-ab3a0af5}
}